Jubilant Pharmova Limited (JUBLPHARMA.NS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Priyavrat Bhartia MBA | MD & Director | 67.47M | -- | 1976 |
| Mr. Arjun Shanker Bhartia | Joint MD & Director | 67.47M | -- | 1987 |
| Mr. Arvind Chokhany | Group CFO & Whole-Time Director | 44.78M | -- | 1972 |
| Mr. Prakash Chandra Bisht B.Com., CA | Executive VP of Group Accounts | -- | -- | 1965 |
| Surajit Pal | Head of Investor Relations | -- | -- | -- |
| Mr. Sanjay Gupta A.C.M.A., B.Com., L.L.B. | Executive VP & Head of Legal | -- | -- | 1966 |
| Mr. Naresh Kapoor | Company Secretary & Compliance Officer | 6.86M | -- | 1974 |
| Shantanu Jha | Group Chief Human Resources Officer | -- | -- | -- |
| Mr. Rajagopal Sankaraiah B.Sc., CA, F.C.A. | Advisor | 67.29M | -- | 1959 |
| Mr. A. P. Srivastava B.A., BA | Senior Vice President of Corporate Affairs | -- | -- | 1946 |
Jubilant Pharmova Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
Corporate Governance
Upcoming Events
July 17, 2025 at 10:59 AM UTC - July 21, 2025 at 12:00 PM UTC
Jubilant Pharmova Limited Earnings Date
July 24, 2025 at 12:00 AM UTC
Ex-Dividend Date
Recent Events
Recent Events Information Not Available